Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P W Manley

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Biochemical Pharmacology|October 15, 1987
Dibenzoquinazoline diones as antihypertensive cyclic guanosine monophosphate phosphodiesterase inhibitorsR F Booth, S P Buckham, D O Lunt, et al.
Leukemia|September 14, 2007
Comparison of nilotinib and imatinib inhibition of FMS receptor signaling, macrophage production and osteoclastogenesisN Brownlow, A E Russell, H Saravanapavan, et al.
Thrombosis and Haemostasis|April 8, 1988
Effect of SC 38249, a novel substituted imidazole, on platelet aggregation in vitro and in vivoN Lad, A C Honey, D O Lunt, et al.
European Journal of Cancer (Oxford, England : 1990)|January 17, 2003
Imatinib: a selective tyrosine kinase inhibitorP W Manley, S W Cowan-Jacob, E Buchdunger, et al.
Leukemia|December 21, 2011
Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinibE Weisberg, A K Azab, P W Manley, et al.
Journal of Medicinal Chemistry|September 1, 1987
Structure-activity relationships in an imidazole-based series of thromboxane synthase inhibitorsP W Manley, N M Allanson, R F Booth, et al.
Journal of Medicinal Chemistry|October 1, 1987
Thromboxane synthase inhibitors. Synthesis and pharmacological activity of (R)-, (S)-, and (+/-)-2,2-dimethyl-6-[2-(1H-imidazol-1-yl)-1-[[(4-methoxyphenyl)- methoxy]methyl]ethoxy]hexanoic acidsP W Manley, D P Tuffin, N M Allanson, et al.
Platelets|November 4, 2010
5-[6-1 -(Cyclohexyl-1 H-tetrazol-5-YL)hexyl]-1,8-naphthyridin-2-(1H)-one, SC-44368, a Potent Anti-aggregatory Agent which Selectively Inhibits Platelet Cyclic AMP PhosphodiesteraseR F Booth, P W Manley, S P Buckham, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 26, 2017
Midostaurin: a magic bullet that blocks mast cell expansion and activationP Valent, C Akin, K Hartmann, et al.
Leukemia|September 10, 2015
Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growthB Peter, G E Winter, K Blatt, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Biochemical Pharmacology|October 15, 1987
Dibenzoquinazoline diones as antihypertensive cyclic guanosine monophosphate phosphodiesterase inhibitorsR F Booth, S P Buckham, D O Lunt, et al.
Leukemia|September 14, 2007
Comparison of nilotinib and imatinib inhibition of FMS receptor signaling, macrophage production and osteoclastogenesisN Brownlow, A E Russell, H Saravanapavan, et al.
Thrombosis and Haemostasis|April 8, 1988
Effect of SC 38249, a novel substituted imidazole, on platelet aggregation in vitro and in vivoN Lad, A C Honey, D O Lunt, et al.
European Journal of Cancer (Oxford, England : 1990)|January 17, 2003
Imatinib: a selective tyrosine kinase inhibitorP W Manley, S W Cowan-Jacob, E Buchdunger, et al.
Leukemia|December 21, 2011
Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinibE Weisberg, A K Azab, P W Manley, et al.
Journal of Medicinal Chemistry|September 1, 1987
Structure-activity relationships in an imidazole-based series of thromboxane synthase inhibitorsP W Manley, N M Allanson, R F Booth, et al.
Journal of Medicinal Chemistry|October 1, 1987
Thromboxane synthase inhibitors. Synthesis and pharmacological activity of (R)-, (S)-, and (+/-)-2,2-dimethyl-6-[2-(1H-imidazol-1-yl)-1-[[(4-methoxyphenyl)- methoxy]methyl]ethoxy]hexanoic acidsP W Manley, D P Tuffin, N M Allanson, et al.
Platelets|November 4, 2010
5-[6-1 -(Cyclohexyl-1 H-tetrazol-5-YL)hexyl]-1,8-naphthyridin-2-(1H)-one, SC-44368, a Potent Anti-aggregatory Agent which Selectively Inhibits Platelet Cyclic AMP PhosphodiesteraseR F Booth, P W Manley, S P Buckham, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 26, 2017
Midostaurin: a magic bullet that blocks mast cell expansion and activationP Valent, C Akin, K Hartmann, et al.
Leukemia|September 10, 2015
Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growthB Peter, G E Winter, K Blatt, et al.
Pageof 3